Exercise, Cancer and Cognition: The ECCO-Study

NCT ID: NCT04789187

Last Updated: 2021-03-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

126 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-01

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The "ECCO"-study evaluates the efficacy of simultaneous controlled exercise during neo/-adjuvant chemotherapy in breast cancer patients and its effects on neurocognition.

In this study the investigators examine the benefits of the individualized high intensity training program on a cancer related cognitive impairment.

Changes in patients' cognition are evaluated by neuropsychological testing. Possible structural changes are detected with MRI volumetry. Biomarkers connected to Cancer Related Cognitive Impairment (CRCI) and chemotherapy related inflammatory processes which impair cognition, respectively, will be assessed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: Epidemiological research indicates that increased levels of physical activity are associated with decreased breast cancer risk and mortality. Thereby, exercise programs can substantially increase patients' quality of life during and after treatment. Up to 80% of breast cancer patients demonstrate a decrease in their cognitive capacity, summarized as the symptom-complex "Cancer Related Cognitive Impairment (CRCI)". Most frequently reported impairments are mild to moderate deficits in processing speed, attention, memory and executive functions. In about 35% of affected patients, cognitive symptoms persist for months, or even years, after completion of medical treatment, impairing daily functioning, limiting ability to return to work and decreasing overall quality of life. Recent studies indicate a key role of inflammatory pathways in the CRCI genesis. Attention to physical activity therefore as a potential supportive care option is increasing. Anyhow, evidence for positive effects of exercise on CRCI is still lacking.

Patients and Methods: This prospective, two-arm, 1:1 randomized, controlled trial aims to investigate the influence of high-intensity training interventions accompanying neo/-adjuvant chemotherapy on CRCI in 126 patients with early breast cancer on cognitive performance measured by the California Verbal Learning Test (CVLT). Secondary endpoints include subjective markers and tests for cognitive performance and inflammatory biomarkers as TNF-α, IL-6, IL-1α, IL-1ß which are suspected to be involved in the pathogenesis of CRCI. As cognitive impairments are believed to be connected to either functional and/or morphological hippocampal damage due to chemotherapy, head MRIs and hippocampal volume measurements will be performed. In addition to a heart rate controlled home-based endurance and strength training for one year, participants in the intervention group will perform a supervised high-intensity interval training (HIIT) exercise program at least once a week. This study will help to clarify whether a long-term supervised exercise intervention program affects CRCI in breast cancer patients and help to reason underlying mechanisms and the pathogenesis of the chemobrain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized Controlled Trial
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Outcome Assessors
Pseudonymization

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A: Exercise intervention arm

Group Type ACTIVE_COMPARATOR

High-Intensity-Interval-Training

Intervention Type PROCEDURE

Defined exercise program up to four times per week including high-intensity-interval-training for one year of active study intervention.

Arm B: Control arm

Group Type PLACEBO_COMPARATOR

General Physical Activity Recommendations

Intervention Type PROCEDURE

Patients will be given general physical activity recommendations during chemotherapy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High-Intensity-Interval-Training

Defined exercise program up to four times per week including high-intensity-interval-training for one year of active study intervention.

Intervention Type PROCEDURE

General Physical Activity Recommendations

Patients will be given general physical activity recommendations during chemotherapy.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed breast cancer and planned neo- and adjuvant chemotherapy
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Age 18 - 70 years
* Adequate hematologic functions 28d prior to randomization (Platelet count over 50 G/L, Hemoglobin over 8 g/dL)
* Able to perform exercise according to protocol
* Signed informed consent prior to randomization
* Fluid in German

Exclusion Criteria

* Significant comorbid conditions precluding participation in a physical activity program (investigators decision)
* Anamnestic cognitive impairment or psychological disorders
* Disabled patients unable to participate in the physical activity program or performing cognitive tests
* Vigorous physical activity of \>300 minutes weekly within the last year before diagnosis of breast cancer 8.3
* Patients unwilling to complete endurance exercise or complete all questionnaires related to the study
* Past or current history of other malignant neoplasms other than breast cancer in the last 5 years except basal cell carcinoma of the skin and/or in situ carcinoma of the cervix
* Clinically significant cardiovascular disease (including myocardial infarction \< 6 month before randomization, unstable angina, symptomatic congestive heart failure NYHA II-IV, serious uncontrolled cardiac arrhythmia, preexcitation syndromes (eg Wolff-Parkinson-White-Syndrome), high grade or complete AV-Block, left bundle branch block, permanent pacemaker stimulation, uncontrolled hypertension (systolic blood pressure \>160 mmHg), aortic valve stenosis, moderate to high-grade valve disease, endo-, myo-, pericarditis, acute aortic dissection, acute pulmonary embolism, acute phlebothrombosis of the lower extremity
* Current pregnancy or plans to become pregnant within the next year after study entry (Pregnancy tests are included in clinical routine before every chemotherapy)
* Signs of severe morphological brain damage in the baseline screening
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

German Sport University, Cologne

OTHER

Sponsor Role collaborator

University of Graz

OTHER

Sponsor Role collaborator

Charite University, Berlin, Germany

OTHER

Sponsor Role collaborator

Charles University, Czech Republic

OTHER

Sponsor Role collaborator

Johannes Kepler University of Linz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Milan Vosko, MD, PhD

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Milan R Vosko, MD, PhD

Role: STUDY_CHAIR

Johannes Kepler University of Linz

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kepler University Hospital

Linz, Upper Austria, Austria

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Milan R Vosko, MD, PhD

Role: CONTACT

+435768083 ext. 6672

David Kiesl, MD

Role: CONTACT

+43768083 ext. 1610

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

David Kiesl, MD

Role: primary

+435768083 ext. 1610

Milan R Vosko, MD, PhD

Role: backup

+43768083 ext. 6672

References

Explore related publications, articles, or registry entries linked to this study.

Kiesl D, Kuzdas-Sallaberger M, Fuchs D, Brunner S, Kommenda R, Tischler C, Hornich H, Akbari K, Kellermair J, Blessberger H, Ocenasek H, Hofmann P, Zimmer P, Vosko MR. Protocol for the Exercise, Cancer and Cognition - The ECCO-Study: A Randomized Controlled Trial of Simultaneous Exercise During Neo-/Adjuvant Chemotherapy in Breast Cancer Patients and Its Effects on Neurocognition. Front Neurol. 2022 Mar 25;13:777808. doi: 10.3389/fneur.2022.777808. eCollection 2022.

Reference Type DERIVED
PMID: 35401389 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1191/2018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Acute Exercise on Cognitive Functions
NCT01241851 UNKNOWN EARLY_PHASE1